利替利单抗治疗狼疮的随机安慰剂对照2期研究中的药效学效应:I型干扰素相关基因表达和细胞因子快速且持续降低
在随机2期LILAC试验A部分(系统性红斑狼疮)和B部分(皮肤型狼疮伴或不伴系统性红斑狼疮)中,利替利单抗使基线干扰素基因签名高的患者干扰素基因签名评分和IFNα浓度快速、显著且持续降低,且与临床反应相关。
要点
- 基线时多数患者干扰素基因签名高(79-91%)。
- A部分450 mg组及B部分150 mg和450 mg组干扰素基因签名评分和IFNα浓度较安慰剂快速、显著且持续降低。
- A部分IFNα降低与临床反应指标相关;B部分干扰素基因签名评分和IFNα浓度呈剂量反应关系,与CLASI-A评分类似。
核心结论
- 利替利单抗给药导致干扰素基因签名评分和IFNα浓度降低,这些药效学效应与临床反应相关。
- 这些发现支持利替利单抗的作用机制及其在更大规模系统性红斑狼疮或皮肤型狼疮患者研究中的继续评估。
研究设计与样本
- 随机2期LILAC试验的A部分(系统性红斑狼疮)或B部分(皮肤型狼疮伴或不伴系统性红斑狼疮)中接受利替利单抗(50 mg、150 mg或450 mg)或安慰剂的参与者。
- 全血样本采用22基因面板评估干扰素基因签名评分,A部分120例、B部分131例;血清中测量IFNα及其他干扰素调节的细胞因子浓度,A部分112例、B部分131例。
主要发现
- 基线时多数参与者干扰素基因签名高(79-91%),未报告基线干扰素基因签名低的参与者结果。
- 在干扰素基因签名高的参与者中,A部分450 mg利替利单抗组和B部分150 mg及450 mg利替利单抗组的干扰素基因签名评分和IFNα浓度较安慰剂快速、显著(名义P < 0.05)且持续降低。
- A部分中利替利单抗组的IFNα降低与临床反应指标相关。
- B部分中观察到干扰素基因签名评分和IFNα浓度的剂量反应关系,与采用皮肤型红斑狼疮疾病面积和严重程度指数-活动性(CLASI-A)评分测量的疾病活动度的剂量反应关系相似。
局限性
- 原文未报告基线干扰素基因签名低的参与者结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). METHODS: Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received litifilimab (at 50 mg, 150 mg, or 450 mg) or a placebo were included. IFN gene signature (IFNGS) scores were assessed from whole-blood samples using a 22-gene panel in 120 and 131 participants (parts A and B, respectively). IFNα and other IFN-regulated cytokine concentrations were measured in serum in 112 and 131 participants (parts A and B, respectively). RESULTS: Most participants were IFNGS-high at baseline (79-91%), and no baseline IFNGS-low participant results were reported. In IFNGS-high participants, litifilimab induced rapid, significant (nominal P < 0.05), and sustained reductions in IFNGS scores and IFNα concentrations versus a placebo for litifilimab at 450 mg in part A and for litifilimab at 150 mg and 450 mg in part B. In part A, IFNα reductions with litifilimab were correlated with clinical response measures. In part B, dose-response relationships for IFNGS score and IFNα concentration were observed, similar to those for disease activity measured with the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score. CONCLUSION: Administration of litifilimab resulted in reductions in both IFNGS scores and IFNα concentrations, pharmacodynamic effects that correlated with clinical responses. These findings support the mechanism of action of litifilimab and its continued evaluation in larger studies of patients with SLE or CLE.
引用
- Furie R, Werth VP, Milliman E, et al. Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo-Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon-Associated Gene Expression and Cytokines. Arthritis Rheumatol. 2025. PMID: 40488251. doi:10.1002/art.43271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。